Nurix Therapeutics, Inc. announced on December 6, 2025, new clinical data on its BTK degrader, bexobrutideg (NX-5948), showing an 83% objective response rate in patients with relapsed chronic lymphocytic leukemia and poor prognosis features, as well as a 75% response rate in Waldenström macroglobulinemia patients. This filing is significant for the company's ongoing clinical trials and product development.